Multiple
Sclerosis (MS) Drugs
|
|
|
Avonex ®
|
(interferon beta-1a)
|
| |
MS Drugs - Avonex ® Efficacy
|
(Effectiveness of Avonex ®)
|
| |
How effective is Avonex ®?
|
| |
|
% of patients progressing In
disability at 2 years
|
|
Placebo
|
Avonex ®
|
|
34.9 %
|
21.9 %
|
|
| |
|
Number of exacerbations
in Subset (people who completed full 2 years) completing 2 years of
Avonex ®
|
| |
|
No. of exacerbations
|
Placebo
|
Avonex ®
|
|
|
0 |
26 % |
38 % |
|
1 |
30 % |
31 % |
|
2 |
11 % |
18 % |
|
3 |
14 % |
7 % |
|
4 |
18 % |
7 % |
|
| |
|
|
Ref: Jacobs LD, et al, Intramuscular interferon beta-1a
for disease progression in relapsing multiple sclerosis. Ann Neurol
1996;39(3):285-94:
Ref: Avonex® prescribing information |
|
Further data from the Food and Drug Administration (FDA)
|
| |
| Reviewed July 2004 |
|
|
